Harvest One Cannabis Takes a Faster Route to Commercialization


Ryan Allway

November 30th, 2017

Exclusive, News, Top News


Canada’s cannabis industry is expected to become a $22.6 billion industry over the coming years, according to Deloitte, driven by the legalization of adult-use marijuana next year. With many analysts expecting a production shortfall, many licensed producers are accelerating their development timelines to meet growing consumer demand. This has created many opportunities for investors in the space to profit from favorable supply and demand economics.

In this article, we will look at Harvest One Cannabis Inc.’s (TSX-V: HVST) new plans to lease and retrofit an existing timber facility to accelerate its cannabis commercialization timeline.

New Letter of Intent

Harvest One Cannabis recently announced that its wholly-owned subsidiary, United Greeneries Ltd., has entered into a letter of intent with a third party for the lease of a property in Chemainus, BC to accelerate and expand production capacity. As a previous industrial lumber kiln drying plant, the facility has an industrial power supply and usable building envelopes. The team has already begun detailed design work and commenced licensing integration activities.

“The Chemainus Facility will allow United Greeneries to capitalize on supplying the upcoming recreational market in Canada with large volumes of high quality dried cannabis buds,” said Harvest One Cannabis CEO Andreas Gedeon. “The company is committed to aggressively pursuing the opportunities at hand and to continue its successful approach of providing shareholders with targeted and substantial value in this thriving industry.”

Management believes that it will be able to commence cultivation activities next year with an initial annual capacity of approximately 8,000 kilograms. In terms of capital expenditure, the team anticipates covering the retrofitting costs with its current cash balance without need for additional financing. The LOI also provides UG with a lease option on a further eight acres on the site, which could be developed to ultimately produce more than 35,000 kilograms per year on a full build out and expansion basis.

A Better Alternative

Harvest One Cannabis’ previously planned Duncan facility expansion would have been a greenhouse operation that would have taken longer to commercialize than the Chemainus Facility. In addition to its shortened timetable, the Chemainus Facility will be an indoor growing environment capable of producing higher quality cannabis instead of extraction grade greenhouse cannabis. This could open the door to higher margin opportunities than were previously possible.

The Duncan facility, with its 1,000 kilogram current annual capacity, will remain as a base of operations for the company on Vancouver Island with a focus on increasing capacity through an expansion plan at the nearby Chemainus Facility. The existing facility’s proximity to the new facility is beneficial as the two locations will complement each other as United Greeneries’ business grows.

Additional Potential

United Greeneries may be focused squarely on cultivation, but Harvest One Cannabis also owns Satipharm AG to provide exposure to the medical side of the business.

Earlier this month, Satipharm AG announced positive Phase I clinical trial results in Israel using its proprietary Gelpell® technology. The results demonstrated the safety and performance of the oral capsule technology, including the effective delivery profile of cannabidiol (CBD) compound to trial subjects. The trial also highlighted the favorable bioavailability of the capsules compared to Sativex – a market leading oral cannabinoid spray from GW Pharmaceuticals plc (GWPH).

The company has since begun Phase II clinical trials to evaluate the efficacy of Satipharm’s capsules in treating refractory epilepsy in children. The completion of the Phase II clinical trial would be a major catalyst toward commercialization of the capsules. In fact, the company could become just the third company to complete Phase II clinical trials next to GW Pharmaceuticals plc and Insys Therapeutics Inc. for refractory epilepsy in children.

Looking Ahead

Harvest One Cannabis Inc. (TSX-V: HVST) represents a compelling opportunity in the cannabis industry given its dual approach to cultivation and medical research. In the cultivation space, United Greeneries’ decision to lease a new facility could accelerate its commercial timetable as Canada prepares for adult use legalization later next year.

For more information, visit the company’s website at www.harvestone.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading